Naiyer A. Rizvi - Concepedia

Author

Naiyer A. Rizvi

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Grohe, Christian, N A Rizvi, N Rizvi, N. A. Rizvi, N. Rizvi, N.A. Rizvi, Naiyer A Rizvi, Naiyer A. Rizvi, Naiyer Rizvi, Noor Rizvi

470

Publications

64.4K

Citations

H-Index

116

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Columbia University Irving Medical Center Moffitt Cancer Center Cornell University Bristol-Myers Squibb (United States)

About

Naiyer A. Rizvi is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	49	133	20.1K
2	Health Sciences	19	27	1.9K
3	Natural Sciences	2	2	60
4	Public Health	2	2	45
5	Engineering	1	1	301

Naiyer A. Rizvi

211

Publications

62.6K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei, L. Paz-Ares, Leora Horn, New England Journal of Medicine	2015	9.3K
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Science	2015	7.8K
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon, Naiyer A. Rizvi, Rina Hui, New England Journal of Medicine	2015	6.1K
Tumor mutational load predicts survival after immunotherapy across multiple cancer types Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Nature Genetics Cancer ImmunosurveillanceTumor HeterogeneityMedicineImmunologyPathology	2019	4.2K
Nivolumab plus Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, New England Journal of Medicine	2013	4.2K
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal, Science T-regulatory CellImmunologyPathologyRegulatory T CellsT Cell Immunoreactivity	2016	3K
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Naiyer A. Rizvi, Julien Mazières, David Planchard, The Lancet Oncology Checkmate 063Single-arm TrialMedicineImmunologyImmune Checkpoint Inhibitor	2015	1.4K
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Scott Gettinger, Leora Horn, Leena Gandhi, Journal of Clinical Oncology	2015	1.2K
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy Diego Chowell, Luc G.T. Morris, Claud Grigg, Science	2017	1.1K
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Antoni Ribas, Omid Hamid, Adil Daud, JAMA	2016	1K

Page 1